EHA 2019 – Outcomes after different intensity of conditioning in acute myeloid leukaemia: the importance of genomic variants


  • Cristina Ferrario — Agenzia Zoe
  • Univadis
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • In patients with acute myeloid leukaemia (AML) in complete remission (CR) before allogenic hematopoietic cell transplantation (allo-HCT), detection of AML-associated genomic variants was associated with increased relapse rate and lower overall survival (OS) in those randomized to reduced intensity conditioning (RIC) compared to those receiving myeloablative conditioning (MAC).
  • Interventions for AML patients with measurable residual disease (MRD) can result in improved survival.

Why this matters

  • AML patients are at risk of relapse after allo-HCT and MRD status before transplant has been shown to be prognostic.
  • The randomized, phase 3 trial BTN CTN 0901 compared outcomes by conditioning intensity showing a survival benefit in patients receiving MAC, with over half of the patients receiving RIC relapsing within 18 months after transplant.
  • It is currently unknown if modulating the intensity of conditioning in patients positive for MRD can prevent relapse and improve survival.

Study design

  • Pre-transplant blood samples from 188 adult AML patients from BTN CTN 0901 trial were tested using ultra-deep next-generation DNA sequencing (udNGS).
  • MAC and RIC regimens were equally represented and patients were well matched for baseline characteristics.
  • The aim of the study was to determine whether a higher intensity conditioning in patients with genomic evidence of residual disease before allo-HCT improves outcomes after the transplant.

Key results

  • 31% of MAC and 33% of RIC patients did not show AML-associated genomic variants in pre-transplant blood samples and had similar OS at 3 years.
  • When detectable genomic variants were present, survival was significantly different between MAC and RIC arms (3-years OS: 61% vs. 44%, respectively; p=0.02).
  • In multivariate analysis for patients with detectable variants, adjusting for disease risk and donor group, RIC was associated with increased relapse (HR 5.98, p